Equities research analysts predict that Hologic, Inc. (NASDAQ:HOLX) will post sales of $806.24 million for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Hologic’s earnings, with estimates ranging from $796.54 million to $814.80 million. Hologic posted sales of $802.90 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 0.4%. The business is expected to issue its next earnings results after the market closes on Wednesday, November 7th.
On average, analysts expect that Hologic will report full year sales of $3.21 billion for the current year, with estimates ranging from $3.20 billion to $3.22 billion. For the next fiscal year, analysts expect that the company will post sales of $3.33 billion, with estimates ranging from $3.27 billion to $3.38 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Hologic.
Hologic (NASDAQ:HOLX) last issued its earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.02. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. The company had revenue of $824.00 million for the quarter, compared to the consensus estimate of $800.14 million.
Several equities research analysts have recently commented on HOLX shares. Bank of America downgraded shares of Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the company from $47.00 to $42.00 in a research note on Thursday, September 13th. BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Thursday, August 16th. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday. Canaccord Genuity boosted their target price on shares of Hologic from $40.00 to $41.00 and gave the company a “hold” rating in a research note on Thursday, September 27th. Finally, Cowen restated a “buy” rating and issued a $45.00 target price on shares of Hologic in a research note on Wednesday, August 1st. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $44.47.
Shares of NASDAQ:HOLX traded up $0.70 on Wednesday, hitting $40.04. The stock had a trading volume of 2,086,350 shares, compared to its average volume of 2,324,738. Hologic has a twelve month low of $35.10 and a twelve month high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29. The company has a market capitalization of $11.15 billion, a PE ratio of 19.72, a P/E/G ratio of 2.01 and a beta of 0.67.
In other Hologic news, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $39.54, for a total transaction of $524,181.78. Following the completion of the sale, the director now directly owns 167,701 shares of the company’s stock, valued at approximately $6,630,897.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the business’s stock in a transaction dated Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total value of $142,635.50. Following the sale, the insider now directly owns 16,520 shares of the company’s stock, valued at $685,580. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,661 shares of company stock worth $1,927,174. 0.88% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in HOLX. Bank of Montreal Can boosted its holdings in shares of Hologic by 37.0% in the 3rd quarter. Bank of Montreal Can now owns 370,187 shares of the medical equipment provider’s stock valued at $15,169,000 after buying an additional 99,888 shares during the last quarter. Lincoln Capital Corp acquired a new stake in shares of Hologic in the 3rd quarter valued at approximately $201,000. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Hologic in the 3rd quarter valued at approximately $2,504,000. Royal London Asset Management Ltd. acquired a new stake in shares of Hologic in the 2nd quarter valued at approximately $4,837,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Hologic in the 2nd quarter valued at approximately $5,837,000. 98.65% of the stock is owned by hedge funds and other institutional investors.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Article: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.